Tumor  ||| S:0 E:6 ||| JJ
specific  ||| S:6 E:15 ||| JJ
CD8+  ||| S:15 E:20 ||| CD
T  ||| S:20 E:22 ||| NN
cells  ||| S:22 E:28 ||| NNS
in  ||| S:28 E:31 ||| IN
patients  ||| S:31 E:40 ||| NNS
with  ||| S:40 E:45 ||| IN
lung  ||| S:45 E:50 ||| NN
cancer  ||| S:50 E:57 ||| NN
and  ||| S:57 E:61 ||| CC
healthy  ||| S:61 E:69 ||| JJ
individuals  ||| S:69 E:81 ||| NNS
Lung  ||| S:81 E:86 ||| NNP
cancer ||| S:86 E:92 ||| NN
,  ||| S:92 E:94 ||| ,
one  ||| S:94 E:98 ||| CD
of  ||| S:98 E:101 ||| IN
the  ||| S:101 E:105 ||| DT
leading  ||| S:105 E:113 ||| JJ
causes  ||| S:113 E:120 ||| NNS
of  ||| S:120 E:123 ||| IN
cancer  ||| S:123 E:130 ||| NN
death  ||| S:130 E:136 ||| NN
in  ||| S:136 E:139 ||| IN
the  ||| S:139 E:143 ||| DT
developed  ||| S:143 E:153 ||| JJ
world ||| S:153 E:158 ||| NN
,  ||| S:158 E:160 ||| ,
presents  ||| S:160 E:169 ||| VBZ
with  ||| S:169 E:174 ||| IN
a  ||| S:174 E:176 ||| DT
poor  ||| S:176 E:181 ||| JJ
5-year  ||| S:181 E:188 ||| CD
survival ||| S:188 E:196 ||| NN
,  ||| S:196 E:198 ||| ,
despite  ||| S:198 E:206 ||| IN
improvements  ||| S:206 E:219 ||| NNS
in  ||| S:219 E:222 ||| IN
conventional  ||| S:222 E:235 ||| JJ
treatments  ||| S:235 E:246 ||| NNS
such  ||| S:246 E:251 ||| JJ
as  ||| S:251 E:254 ||| IN
surgery ||| S:254 E:261 ||| NN
,  ||| S:261 E:263 ||| ,
radiotherapy  ||| S:263 E:276 ||| NN
and  ||| S:276 E:280 ||| CC
chemotherapy ||| S:280 E:292 ||| NN
.  ||| S:292 E:294 ||| .
Lung  ||| S:294 E:299 ||| NNP
cancer-directed  ||| S:299 E:315 ||| JJ
immunotherapy  ||| S:315 E:329 ||| NN
promises  ||| S:329 E:338 ||| VBZ
to  ||| S:338 E:341 ||| TO
harness  ||| S:341 E:349 ||| VB
the  ||| S:349 E:353 ||| DT
body ||| S:353 E:357 ||| NN
's  ||| S:357 E:360 ||| POS
ability  ||| S:360 E:368 ||| NN
to  ||| S:368 E:371 ||| TO
mount  ||| S:371 E:377 ||| VB
antitumor  ||| S:377 E:387 ||| JJ
immune  ||| S:387 E:394 ||| JJ
responses  ||| S:394 E:404 ||| NNS
and  ||| S:404 E:408 ||| CC
destroy  ||| S:408 E:416 ||| VB
cancer  ||| S:416 E:423 ||| NN
cells ||| S:423 E:428 ||| NNS
.  ||| S:428 E:430 ||| .
Improving  ||| S:430 E:440 ||| VBG
our  ||| S:440 E:444 ||| PRP$
understanding  ||| S:444 E:458 ||| NN
of  ||| S:458 E:461 ||| IN
tumor  ||| S:461 E:467 ||| NN
biology  ||| S:467 E:475 ||| NN
and  ||| S:475 E:479 ||| CC
the  ||| S:479 E:483 ||| DT
host  ||| S:483 E:488 ||| NN
immune  ||| S:488 E:495 ||| JJ
response  ||| S:495 E:504 ||| NN
promises  ||| S:504 E:513 ||| VBZ
to  ||| S:513 E:516 ||| TO
have  ||| S:516 E:521 ||| VB
a  ||| S:521 E:523 ||| DT
positive  ||| S:523 E:532 ||| JJ
impact  ||| S:532 E:539 ||| NN
on  ||| S:539 E:542 ||| IN
the  ||| S:542 E:546 ||| DT
development  ||| S:546 E:558 ||| NN
of  ||| S:558 E:561 ||| IN
novel  ||| S:561 E:567 ||| JJ
therapeutic  ||| S:567 E:579 ||| JJ
strategies  ||| S:579 E:590 ||| NNS
for  ||| S:590 E:594 ||| IN
this  ||| S:594 E:599 ||| DT
disease ||| S:599 E:606 ||| NN
.  ||| S:606 E:608 ||| .
This  ||| S:608 E:613 ||| DT
article  ||| S:613 E:621 ||| NN
will  ||| S:621 E:626 ||| MD
present  ||| S:626 E:634 ||| VB
our  ||| S:634 E:638 ||| PRP$
current  ||| S:638 E:646 ||| JJ
understanding  ||| S:646 E:660 ||| NN
on  ||| S:660 E:663 ||| IN
immunotherapy  ||| S:663 E:677 ||| NN
from  ||| S:677 E:682 ||| IN
the  ||| S:682 E:686 ||| DT
perspective  ||| S:686 E:698 ||| NN
of  ||| S:698 E:701 ||| IN
the  ||| S:701 E:705 ||| DT
CD8+  ||| S:705 E:710 ||| JJ
cytolytic  ||| S:710 E:720 ||| JJ
T  ||| S:720 E:722 ||| NN
cell  ||| S:722 E:727 ||| NN
response  ||| S:727 E:736 ||| NN
in  ||| S:736 E:739 ||| IN
lung  ||| S:739 E:744 ||| NN
cancer  ||| S:744 E:751 ||| NN
and  ||| S:751 E:755 ||| CC
how  ||| S:755 E:759 ||| WRB
elucidation  ||| S:759 E:771 ||| NNS
of  ||| S:771 E:774 ||| IN
the  ||| S:774 E:778 ||| DT
mechanisms  ||| S:778 E:789 ||| NNS
that  ||| S:789 E:794 ||| WDT
affect  ||| S:794 E:801 ||| VBP
T-cell  ||| S:801 E:808 ||| JJ
memory  ||| S:808 E:815 ||| NN
lineage  ||| S:815 E:823 ||| NN
commitment  ||| S:823 E:834 ||| NN
could  ||| S:834 E:840 ||| MD
improve  ||| S:840 E:848 ||| VB
the  ||| S:848 E:852 ||| DT
outcome  ||| S:852 E:860 ||| NN
of  ||| S:860 E:863 ||| IN
current  ||| S:863 E:871 ||| JJ
immunotherapeutic  ||| S:871 E:889 ||| JJ
attempts ||| S:889 E:897 ||| NNS
.  ||| S:897 E:899 ||| .
